'We need to do more': Merck CEO Rob Davis highlights M&A, deals strategy ahead of '28 Keytruda patent cliff
With megablockbuster Keytruda’s patent cliff looming in 2028, Merck has made some bold M&A moves in an attempt to find its next big moneymaker, including …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
